Article
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Clinical lung cancer - 1 May 2014
Gridelli Cesare, de Marinis Filippo, Cappuzzo Federico, Di Maio Massimo, Hirsch Fred R, Mok Tony, Morgillo Floriana, Rosell Rafael, Spigel David R, Yang James Chih-Hsin, Ciardiello Fortunato
Abstract excerpt
The availability of targeted drugs has made the assessment of the EGFR mutation and ALK rearrangement critical in choosing the optimal treatment for patients with advanced non-small-cell lung cancer (NSCLC). In May 2013, the Italian Association of Thoracic Oncology (AIOT) organized an International Experts Panel Meeting to review strengths and limitations of the available evidence for the diagnosis and treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.